Javlor

Vinflunine, the active ingredient in Javlor, is a Vinca alkaloid derivative presented as a 5 mg per vial injectable solution for intravenous use. It is indicated for metastatic urothelial carcinoma after platinum‑based chemotherapy in adult patients.

GNH USA supplies Javlor as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Javlor (vinflunine) is used in the treatment of urothelial cancers that have progressed after standard chemotherapy.

Metastatic urothelial carcinoma: provides a therapeutic option after platinum‑based chemotherapy failure.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Nausea and vomiting: gastrointestinal upset common during infusion. - Constipation: decreased bowel motility. - Fatigue: general tiredness and weakness. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: life‑threatening infection risk. - Hemorrhage: bleeding complications due to platelet suppression. - Cardiac toxicity: arrhythmias or reduced cardiac function. - Severe allergic reactions: anaphylaxis or infusion‑related hypersensitivity. - Renal failure: impaired kidney function requiring monitoring.

Before initiating therapy with Javlor, clinicians should assess patient suitability and monitor for potential complications. - Monitor blood counts: perform regular complete blood count to detect neutropenia or anemia. - Assess renal function: evaluate creatinine clearance before each cycle. - Evaluate hepatic function: check liver enzymes as the drug is metabolized hepatically. - Avoid in patients with known hypersensitivity to vinflunine or other Vinca alkaloids. - Use caution in pregnancy: safety category unknown; weigh benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinflunine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other microtubule inhibitors: additive toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinflunine exposure. - CYP3A4 inducers (e.g., rifampicin): reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other myelosuppressive agents: enhanced bone‑marrow suppression. - Diuretics: potential electrolyte disturbances when combined with renal effects.